細胞動力 CYTK 深 滬
等待開盤 09-11 09:30:00 美东时间
51.04
-0.460
-0.89%
華盛通- 最 高51.75
- 今 開51.18
- 成交量 80.86万股
- 最 低 50.05
- 昨 收 51.50
- 總市值 60.74亿
- 52周最高 59.39
- 市盈率 靜 --
- 換手率 0.68%
- 52周最低 29.31
- 委 比 8.89%
- 總股本 1.19亿
- 歷史最高 110.25
- 量 比 0.31
- 振 幅 3.30%
- 歷史最低 0.57
- 每 手 1
- 風險率 15.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%
医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%，肺纤维化治疗取得重大突破；Lululemon周跌17%，此前下调年度利润及销售额预期>>
09-06 10:02
美股牛股 | 医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%
医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%，实验性药物临床数据乐观；MLYS大涨逾80%，高血压新药市场前景广阔>>
09-03 15:53
Cytokinetics Reveals Promising MAPLE-HCM Trial Results
Cytokinetics ( ($CYTK) ) has provided an update. Cytokinetics announced the res...
09-03 05:48
Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action?
Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten.
09-02 22:46
道指开盘跌0.97%，标普500跌1.3%，纳指跌1.7%
百事涨5.8%，激进投资机构Elliott Management已持有其40 亿美元股份。Cytokinetics涨27.2%，aficamten的临床试验显示...
09-02 21:30
Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $72 price target.
09-02 17:55
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine
Aficamten demonstrated superior efficacy to metoprolol in the MAPLE-HCM trial for treating obstructive hypertrophic cardiomyopathy (oHCM). The study showed significant improvement in exercise capacity, symptom burden, and functional class in patients receiving aficamten compared to metoprolol. Aficamten also reduced left ventricular outflow tract gradients and NT-proBNP levels, indicating favorable cardiac remodeling. The results challenge beta-b...
08-30 07:18
Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy — Here's Where He's Investing Instead
A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.
08-27 05:00
Cytokinetics Names Jim Daly to Board of Directors
Cytokinetics, Inc. appoints James M. Daly to its Board of Directors, effective August 19, 2025. Daly brings over 30 years of global biopharmaceutical experience, particularly in commercialization, to the board. Robert I. Blum, CEO, expresses confidence in Daly's contributions as the company advances toward becoming a fully integrated commercial organization. Daly has a strong track record, including leading the launch of Jakafi® at Incyte, and se...
08-20 11:30
Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences, Inc. announced its participation in several investor conferences, including the UBS Precision Medicine Summit in Dana Point, CA, featuring a panel discussion on August 14; the Wells Fargo Healthcare Conference in Boston, MA, with investor meetings on September 4; and the Morgan Stanley Global Healthcare Conference in New York, NY, hosting a fireside chat on September 10. The company, known for its advanced cell analysis solutio...
08-12 20:05
